6-dimethylaminomethyl-nicotinic acid | 789484-63-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6-dimethylaminomethyl-nicotinic acid
• 英文别名: 6-[(dimethylamino)methyl]pyridine-3-carboxylic acid
• CAS: 789484-63-5
• 化学式: C₉H₁₂N₂O₂
• mdl: MFCD13249759
• 分子量: 180.206
• InChiKey: CDFAQVRWSLLZSG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  53.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  6-dimethylaminomethyl-nicotinic acid Na salt 在 盐酸 、 水 作用下， 生成 6-dimethylaminomethyl-nicotinic acid
  参考文献：
  名称：

  WO2006/122011

  摘要：

  公开号：

文献信息

• PYRROLIDINE ARYL-ETHER AS NK3 RECEPTOR ANTAGONISTS
  申请人：Jablonski Philippe

  公开号：US20090042896A1

  公开（公告）日：2009-02-12

  The invention relates to a compound of formula I wherein Ar 1 , Ar 2 , R 1 , R 2 , R 3 , R 4 , n, o, p, and q are as defined herein and to a pharmaceutically active salt thereof, including all stereoisomeric forms, individual diastereoisomers and enantiomers of the compound of formula (I) as well as racemic and non-racemic mixtures thereof. The compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).

  该发明涉及一种化合物，其化学式为I，其中Ar1、Ar2、R1、R2、R3、R4、n、o、p和q如本文所定义，并且涉及其药用活性盐，包括化合物(I)的所有立体异构形式、单个对映体异构体和对映体，以及其外消旋和非外消旋混合物。这些化合物是高潜力的NK-3受体拮抗剂，用于治疗抑郁症、疼痛、精神病、帕金森病、精神分裂症、焦虑和注意力缺陷多动障碍（ADHD）。
• Pyrrolidine aryl-ether as NK-3 receptor antagonists
  申请人：Hoffmann—LA Roche Inc.

  公开号：US08012998B2

  公开（公告）日：2011-09-06

  The invention relates to a compound of formula I wherein Ar1, Ar2, R1, R2, R3, R4, n, o, p, and q are as defined herein and to a pharmaceutically active salt thereof, including all stereoisomeric forms, individual diastereoisomers and enantiomers of the compound of formula (I) as well as racemic and non-racemic mixtures thereof. The compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).

  本发明涉及公式I的化合物，其中Ar1，Ar2，R1，R2，R3，R4，n，o，p和q如本文所定义，并涉及其药物活性盐，包括公式（I）化合物的所有立体异构体形式，单个非对映异构体和对映异构体以及它们的外消旋和非外消旋混合物。这些化合物是高潜力的NK-3受体拮抗剂，用于治疗抑郁症、疼痛、精神病、帕金森病、精神分裂症、焦虑症和注意力缺陷多动障碍（ADHD）。
• Thiazole compounds and methods of use
  申请人：Zhang Suoming

  公开号：US20070004711A1

  公开（公告）日：2007-01-04

  The present invention provides compounds, salts and hydrates of Formula I, wherein the variables Ar 1 , R 2 , R 3 , R 4 , r, q, and t are defined herein. Certain compounds of Formula I described herein possess potent antiviral activity. The invention also provides compounds of Formula I that are potent and/or selective inhibitors of Hepatitis C virus replication. Certain compounds described herein inhibit assembly of the HCV replication complex. The invention also provides pharmaceutical compositions containing one or more compounds of Formula I, or a salt, solvate, or acylated prodrug of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain infectious diseases by administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease. These infectious diseases include viral infections, particularly HCV infections. The invention is particularly includes methods of treating human patients suffering from an infectious disease, but also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from an infectious disease. Methods of treatment include administering a compound of Formula I as a single active agent or administering a compound of Formula I in combination with on or more other therapeutic agent.
• HETEROARYL SUBSTITUTED THIAZOLES
  申请人：Wang Xiangzhu

  公开号：US20090041720A1

  公开（公告）日：2009-02-12

  The invention provides heteroaryl substituted thiazolo compounds of Formula I and II and pharmaceutically acceptable salts thereof. The variables A and R 3 to R 7 are defined herein. The invention also includes methods for preparing compounds and salts of Formula I and II. The present invention also includes pharmaceutical compositions containing heteroaryl substituted thiazolo compounds and methods for using heteroaryl substituted thiazolo compounds, including methods for using the compounds in the treatment of hepatitis C virus.
• THIAZOLE COMPOUNDS AND METHODS OF USE
  申请人：Zhang Suoming

  公开号：US20120108576A1

  公开（公告）日：2012-05-03

  The present invention provides compounds, salts and hydrates of Formula I, wherein the variables Ar 1 , R 2 , R 3 , R 4 , r, q, and t are defined herein. Certain compounds of Formula I described herein possess potent antiviral activity. The invention also provides compounds of Formula I that are potent and/or selective inhibitors of Hepatitis C virus replication. Certain compounds described herein inhibit assembly of the HCV replication complex. The invention also provides pharmaceutical compositions containing one or more compounds of Formula I, or a salt, solvate, or acylated prodrug of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain infectious diseases by administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease. These infectious diseases include viral infections, particularly HCV infections. The invention is particularly includes methods of treating human patients suffering from an infectious disease, but also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from an infectious disease. Methods of treatment include administering a compound of Formula I as a single active agent or administering a compound of Formula I in combination with on or more other therapeutic agent.